Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 5/2016

01-05-2016

Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer

Authors: Rajan T. Gupta, Benjamin Spilseth, Nayana Patel, Alison F. Brown, Jinxing Yu

Published in: Abdominal Radiology | Issue 5/2016

Login to get access

Abstract

Multiparametric MRI (mpMRI) represents a growing modality for the non-invasive evaluation of prostate cancer (PCa) and is increasingly being used for patients with persistently elevated PSA and prior negative biopsies, for monitoring patients in active surveillance protocols, for preoperative characterization of cancer for surgical planning, and in planning for MRI-targeted biopsy. The focus of this work is twofold. First, we review the key role of T2-weighted imaging (T2WI) in mpMRI, specifically outlining how it is used for anatomic evaluation of the prostate, detection of clinically significant PCa, assessment of extraprostatic extension (EPE), and mimics of PCa on this sequence. We will also discuss optimal technical acquisition parameters for this sequence and recent technical advancements in T2WI. Second, we will delineate the role that mpMRI plays in the staging of PCa and describe the implications of the information that mpMRI can provide in determining the most appropriate management plan for the patient with PCa.
Literature
1.
2.
Tay KJ, Mendez M, Moul JW, Polascik TJ (2015) Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol 25(3):185–190CrossRefPubMed
3.
Turkbey B, Pinto PA, Mani H, et al. (2010) Prostate Cancer: value of multiparametric MR imaging at 3 T for detection—histopathologic correlation. Radiology 255(1):89–99CrossRefPubMedPubMedCentral
4.
Tan CH, Paul Hobbs B, Wei W, Kundra V (2015) Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 204(4):W439–W448CrossRefPubMed
5.
Xylinas E, Yates D, Renard-Penna R, et al. (2013) Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. World Journal of Urology 31(4):881–886CrossRefPubMed
6.
Mullerad M, Hricak H, Kuroiwa K, et al. (2005) Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 174(6):2158–2163CrossRefPubMed
7.
Sanchez-Chapado M, Angulo JC, Ibarburen C, et al. (1997) Comparison of digital rectal examination, transrectal ultrasonography, and multicoil magnetic resonance imaging for preoperative evaluation of prostate cancer. Eur Urol 32(2):140–149PubMed
8.
Steyn JH, Smith FW (1984) Nuclear magnetic resonance (NMR) imaging of the prostate. Br J Urol 56(6):679–681CrossRefPubMed
9.
Dooms GC, Hricak H (1986) Magnetic resonance imaging of the pelvis: prostate and urinary bladder. Urol Radiol 8(3):156–165CrossRefPubMed
10.
Hricak H, Dooms GC, McNeal JE, et al. (1987) MR imaging of the prostate gland: normal anatomy. AJR Am J Roentgenol 148(1):51–58CrossRefPubMed
11.
Rifkin MD, Zerhouni EA, Gatsonis CA, et al. (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med. 323(10):621–626CrossRefPubMed
12.
13.
14.
Zand KR, Reinhold C, Haider MA (2007) Artifacts and pitfalls in MR imaging of the pelvis. J Magn Reson Imaging 26(3):480–497CrossRefPubMed
15.
Heijmink SW, Futterer JJ, Hambrock T, et al. (2007) Prostate cancer: body-array versus endorectal coil MR imaging at 3 T–comparison of image quality, localization, and staging performance. Radiology 244(1):184–195CrossRefPubMed
16.
Wasserman NF (2006) Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am 44(5):689–710, viii.
17.
Rosenkrantz AB, Taneja SS (2014) Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. AJR Am J Roentgenol 202(1):109–120CrossRefPubMed
18.
19.
Gupta RT, Kauffman CR, Garcia-Reyes K, et al. (2015) Apparent diffusion coefficient values of the benign central zone of the prostate: comparison with low- and high-grade prostate cancer. AJR Am J Roentgenol 205(2):331–336CrossRefPubMed
20.
Vargas HA, Akin O, Franiel T, et al. (2012) Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology 262(3):894–902CrossRefPubMedPubMedCentral
21.
McNeal JE, Redwine EA, Freiha FS, et al. (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12(12):897–906CrossRefPubMed
22.
Rosenkrantz AB, Verma S, Turkbey B (2015) Prostate cancer: top places where tumors hide on multiparametric MRI. AJR Am J Roentgenol 204(4):W449–W456CrossRefPubMed
23.
Rosenkrantz AB, Kim S, Campbell N, et al. (2015) Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. AJR Am J Roentgenol 204(3):W266–W272CrossRefPubMed
24.
Cornud F, Rouanne M, Beuvon F, et al. (2012) Endorectal 3D T2-weighted 1 mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D’Amico tumor risk criteria? Eur J Radiol 81(4):e591–e597CrossRefPubMed
25.
Rosenkrantz AB, Neil J, Kong X, et al. (2010) Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR Am J Roentgenol 194(2):446–452CrossRefPubMed
26.
Turkbey B, Albert PS, Kurdziel K, Choyke PL (2009) Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 192(6):1471–1480CrossRefPubMedPubMedCentral
27.
Turkbey B, Mani H, Shah V, et al. (2011) Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 186(5):1818–1824CrossRefPubMed
28.
Delongchamps NB, Beuvon F, Eiss D, et al. (2011) Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 14(3):232–237CrossRefPubMed
29.
Tamada T, Sone T, Higashi H, et al. (2011) Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol 197(3):664–670CrossRefPubMed
30.
Isebaert S, Van den Bergh L, Haustermans K, et al. (2013) Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging 37(6):1392–1401CrossRefPubMed
31.
Chen M, Dang HD, Wang JY, et al. (2008) Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 49(5):602–610CrossRefPubMed
32.
Tan CH, Wei W, Johnson V, Kundra V (2012) Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 199(4):822–829CrossRefPubMedPubMedCentral
33.
Li H, Sugimura K, Kaji Y, et al. (2006) Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 186(3):729–742CrossRefPubMed
34.
Oto A, Kayhan A, Jiang Y, et al. (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257(3):715–723CrossRefPubMed
35.
Hoeks CM, Hambrock T, Yakar D, et al. (2013) Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology 266(1):207–217CrossRefPubMed
36.
Akin O, Sala E, Moskowitz CS, et al. (2006) Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239(3):784–792CrossRefPubMed
37.
Shukla-Dave A, Hricak H, Eberhardt SC, et al. (2004) Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings–initial observations. Radiology 231(3):717–724CrossRefPubMed
38.
Tamada T, Sone T, Jo Y, et al. (2008) Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology 248(2):531–539CrossRefPubMed
39.
Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H (2012) Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology 263(3):751–757CrossRefPubMedPubMedCentral
40.
Ream JM, Rosenkrantz AB (2015) Advances in T1-weighted and T2-weighted imaging in the abdomen and pelvis. Radiol Clin North Am 53(3):583–598CrossRefPubMed
41.
Lane BF, Vandermeer FQ, Oz RC, et al. (2011) Comparison of sagittal T2-weighted BLADE and fast spin-echo MRI of the female pelvis for motion artifact and lesion detection. AJR Am J Roentgenol 197(2):W307–W313CrossRefPubMed
42.
Rosenkrantz AB, Bennett GL, Doshi A, et al. (2015) T2-weighted imaging of the prostate: Impact of the BLADE technique on image quality and tumor assessment. Abdom Imaging 40(3):552–559CrossRefPubMed
43.
Engelbrecht MR, Huisman HJ, Laheij RJ, et al. (2003) Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229(1):248–254CrossRefPubMed
44.
Gibbs P, Tozer DJ, Liney GP, Turnbull LW (2001) Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 46(6):1054–1058CrossRefPubMed
45.
Liney GP, Knowles AJ, Manton DJ, et al. (1996) Comparison of conventional single echo and multi-echo sequences with a fast spin-echo sequence for quantitative T2 mapping: application to the prostate. J Magn Reson Imaging 6(4):603–607CrossRefPubMed
46.
47.
Roebuck JR, Haker SJ, Mitsouras D, et al. (2009) Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging 27(4):497–502CrossRefPubMedPubMedCentral
48.
Yamauchi FI, Penzkofer T, Fedorov A, et al. (2015) Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T2-mapping MRI sequence. Magn Reson Imaging 33(5):525–530CrossRefPubMed
49.
Wu LM, Chen XX, Xuan HQ, et al. (2014) Feasibility and preliminary experience of quantitative T2* mapping at 3.0 T for detection and assessment of aggressiveness of prostate cancer. Acad Radiol 21(8):1020–1026CrossRefPubMed
50.
Kwak JT, Xu S, Wood BJ, et al. (2015) Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. Med Phys 42(5):2368–2378CrossRefPubMedPubMedCentral
51.
Rorvik J, Halvorsen OJ, Albrektsen G, et al. (1999) MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. Eur Radiol 9(1):29–34CrossRefPubMed
52.
Yu KK, Hricak H, Alagappan R, et al. (1997) Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 202(3):697–702CrossRefPubMed
53.
Baco E, Rud E, Vlatkovic L, et al. (2015) Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. J Urol 193(2):466–472CrossRefPubMed
54.
Boesen L, Chabanova E, Logager V, et al. (2015) Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. Eur Radiol 25(6):1776–1785CrossRefPubMed
55.
Pound CR, Partin AW, Epstein JI, Walsh PC (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24(2):395–406CrossRefPubMed
56.
McClure TD, Margolis DJ, Reiter RE, et al. (2012) Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 262(3):874–883CrossRefPubMed
57.
Billing A, Buchner A, Stief C, Roosen A (2014) Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol . doi:10.​1007/​s00345-014-1448-5 PubMed
58.
Brajtbord JS, Lavery HJ, Nabizada-Pace F, Senaratne P, Samadi DB (2011) Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. BJU Int 107(9):1419–1424CrossRefPubMed
59.
Ruprecht O, Weisser P, Bodelle B, Ackermann H, Vogl TJ (2012) MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol 81(3):456–460CrossRefPubMed
60.
Hoeks CM, Barentsz JO, Hambrock T, et al. (2011) Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 261(1):46–66CrossRefPubMed
61.
Futterer JJ, Heijmink SW, Scheenen TW, et al. (2006) Prostate cancer: local staging at 3-T endorectal MR imaging–early experience. Radiology 238(1):184–191CrossRefPubMed
62.
Latchamsetty KC, Borden LS Jr, Porter CR, et al. (2007) Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve? Can J Urol 14(1):3429–3434PubMed
63.
Garcia-Reyes K, Passoni NM, Palmeri ML, et al. (2015) Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging 40(1):134–142CrossRefPubMedPubMedCentral
64.
Mullerad M, Hricak H, Wang L, et al. (2004) Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232(1):140–146CrossRefPubMed
65.
Wibmer A, Vargas HA, Donahue TF, et al. (2015) Diagnosis of Extracapsular Extension of Prostate Cancer on Prostate MRI: Impact of Second-Opinion Readings by Subspecialized Genitourinary Oncologic Radiologists. AJR Am J Roentgenol 205(1):W73–W78CrossRefPubMed
66.
Chandra RV, Heinze S, Dowling R, et al. (2007) Endorectal magnetic resonance imaging staging of prostate cancer. ANZ J Surg 77(10):860–865CrossRefPubMed
67.
Bloch BN, Furman-Haran E, Helbich TH, et al. (2007) Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging–initial results. Radiology 245(1):176–185CrossRefPubMed
68.
Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K (2009) Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol 50(5):562–569CrossRefPubMed
69.
Cerantola Y, Valerio M, Kawkabani Marchini A, et al. (2013) Can 3T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension? Can Urol Assoc J 7(11–12):E699–E703PubMedPubMedCentral
70.
Otto J, Thormer G, Seiwerts M, et al. (2014) Value of endorectal magnetic resonance imaging at 3T for the local staging of prostate cancer. Rofo 186(8):795–802CrossRefPubMed
71.
Xylinas E, Yates DR, Renard-Penna R, et al. (2013) Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. World J Urol 31(4):881–886CrossRefPubMed
72.
Partin AW, Mangold LA, Lamm DM, et al. (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58(6):843–848CrossRefPubMed
73.
Partin AW, Kattan MW, Subong EP, et al. (1997) Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 277(18):1445–1451CrossRefPubMed
74.
Gupta RT, Faridi KF, Singh AA, et al. (2014) Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urol Oncol 32(8):1292–1299CrossRefPubMed
75.
Porcaro AB, Borsato A, Romano M, et al. (2013) Accuracy of preoperative endo-rectal coil magnetic resonance imaging in detecting clinical under-staging of localized prostate cancer. World J Urol 31(5):1245–1251CrossRefPubMed
76.
Hegde JV, Chen MH, Mulkern RV, et al. (2013) Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 85(2):e101–e107CrossRefPubMedPubMedCentral
77.
Chamie K, Sonn GA, Finley DS, et al. (2014) The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology 83(2):369–375CrossRefPubMedPubMedCentral
Metadata
Title
Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer
Authors
Rajan T. Gupta
Benjamin Spilseth
Nayana Patel
Alison F. Brown
Jinxing Yu
Publication date
01-05-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0579-5

Other articles of this Issue 5/2016

Abdominal Radiology 5/2016 Go to the issue

Classics in Abdominal Imaging

Inverted V sign

OriginalPaper

A urologist’s perspective on prostate cancer imaging: past, present, and future

OriginalPaper

Prostate cancer post-treatment follow-up and recurrence evaluation

Commentary

Engaging and educating patients in prostate imaging via social media

Pictorial Essay

A practical primer on PI-RADS version 2: a pictorial essay

OriginalPaper

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits